98 results about "Dextran sodium sulfate" patented technology

The application of the animal bifidobacterium subsp. Lactis BX-245 in relieving the inflammatory bowel disease is characterized in that the animal bifidobacterium subsp. Lactis BX-245 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.26973. The invention also discloses an application of the animal bifidobacterium subsp. Lactis BX-245 in relieving the inflammatory bowel disease. The research aims at discussing the relieving effect of the animal bifidobacterium subsp. Lactis BX-245 on IBD mice induced by dextran sodium sulfate (DSS), and 6-week male C57BL / 6J mice which normally eat and drink water are randomly divided into a normal group (NC group), a model group (IBD group), a common yoghourt (FM group), an animal bifidobacterium subsp. Lactis BX-245 bacterial powder group (BX-245 group) and BX-245 yoghourt (BFM group). The relieving effect of the animal bifidobacterium subsp. Lactis BX-245 and the fermented milk of the animal bifidobacterium subsp. Lactis BX-245 on the symptom of the mouse inflammatory bowel disease is evaluated through weight change, immune factors, targeted metabonomics and metagenomics, and data support is provided for application of the animal bifidobacterium subsp. Lactis BX-245 in products.

The invention discloses lactobacillus reuteri with antioxidant, anti-inflammatory and anti-hypoxia capabilities, the name of the lactobacillus reuteri is QM11, the classification name of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation date of the lactobacillus reuteri is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing on August 5, 2024, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, the preservation number of the lactobacillus reuteri is CGMCC NO.31541, and the preservation number of the lactobacillus reuteri is CGMCC NO.31541. The preservation unit is China General Microbiological Culture Collection Center (CGMCC). The lactobacillus reuteri is separated from faeces of healthy yaks in Qinghai province, has relatively strong acid and cholate tolerance, has relatively good antioxidant and anti-inflammatory capacities, and has a relatively strong inhibition effect on pathogenic bacteria such as yak-derived pathogenic escherichia coli, staphylococcus aureus and salmonella typhimurium; the sodium dextran sulfate induced mouse colitis symptom is relieved, and the hypoxia tolerance of the mouse is improved. The lactobacillus reuteri disclosed by the invention can be used for preparing medicines or microecological preparations for resisting oxidation, inflammation and hypoxia, and has a very wide application prospect.

The invention relates to the technical field of microbial medicines, and particularly discloses Brawler's bacteria EMF75-02B1B and an application of the Brawler's bacteria EMF75-02B1B. The invention discloses Blauria sp. EMF75-02B1B, which is preserved in the Guangdong Microbial Culture Collection Center on September 2, 2024, and the preservation number of the Blauria sp. EMF75-02B1B is GDMCC No: 65084. A mouse model proves that the Brawler bacteria EMF75-02B1B can obviously improve the disease activity index (DAI) of a dextran sodium sulfate induced ulcerative colitis mouse, relieve the weight loss and colon shortening degree of the ulcerative colitis mouse, enhance the intestinal barrier function and relieve inflammatory response.

The invention relates to the technical field of microbial medicines, and in particular discloses a doer's bacterium EMF18-06B1D and an application of the doer's bacterium EMF18-06B1D. The invention relates to a Dorenia phocaeensis EMF18-06B1D, which is preserved in Guangdong Microbial Culture Collection Center on September 2, 2024, and the preservation number of the Dorenia phocaeensis EMF18-06B1D is GDMCC No: 65085. The invention further discloses a preparation method of the Dorenia phocaeensis EMF18-06B1D. A mouse model proves that the polythermia EMF18-06B1D can obviously improve the disease activity index (DAI) of a dextran sodium sulfate induced ulcerative colitis mouse, relieve the weight reduction trend and the colon shortening degree of the ulcerative colitis mouse, and contribute to intestinal barrier function recovery and intestinal inflammatory response reduction.

The invention discloses a preparation method of compound polysaccharide microspheres capable of releasing NO. The preparation method comprises the following steps: cross-linking swallow polysaccharide with L-ARG, and preparing L-ARG-containing swallow polysaccharide hydrogel through a Mannich reaction; then loading EGCG (epigallocatechin gallate) onto the L-ARG-containing swallow polysaccharide hydrogel through a Schiff base reaction, and obtaining the compound polysaccharide microspheres capable of releasing NO by utilizing an emulsification method. The invention also discloses an application thereof. The hydrogel microsphere capable of targeting the colon is prepared, and the hydrogel microsphere can be accurately exploded at the colon part after being swallowed. A dextran sodium sulfate (DSS)-induced IBD mouse model is established to test the drug effect, and the result shows that the compound polysaccharide microspheres have a remarkable treatment effect on DSS-induced ulcerative colitis, can obviously improve the symptoms of ulcerative colitis, and provides a theoretical basis and a clinical basis for new drugs for clinically preventing and treating ulcerative colitis.

The invention relates to the technical field of ulcerative colitis related medicines, in particular to application of honeysuckle polysaccharide in preparation of medicines for treating ulcerative colitis and inflammation related colorectal cancer. According to the technical scheme, it is found that the honeysuckle flower polysaccharide WLJP-025P has an obvious improvement effect on ulcerative colitis induced by dextran sodium sulfate and has an obvious treatment effect on a mouse with colorectal cancer induced by azoxymethane / dextran sodium sulfate (AOM / DSS). The treatment effect of the WLJP-025P is better than that of the honeysuckle aqueous extract and the honeysuckle crude polysaccharide, the WLJP-025P is expected to be developed into a candidate medicinal substance for ulcerative colitis and related colorectal cancer, the technical problem that in the prior art, a medicine which is small in side effect and high in specificity and is used for treating ulcerative colitis is lacked can be solved, and the WLJP-025P has ideal application and popularization prospects.

The invention belongs to the technical field of biological medicines, and particularly relates to application of extracellular vesicle-like particles derived from divaricate saposhnikovia roots in preparation of medicines for preventing and treating intestinal diseases. Research on the physiological efficacy of the extracellular vesicle-like particles from divaricate saposhnikovia root shows that the extracellular vesicle-like particles can relieve colon shortening and colon tissue damage caused by dextran sodium sulfate, relieve intestinal inflammation and promote repair of intestinal barriers including mechanical barriers, chemical barriers and immune barriers. The polypeptide has potential for preparing the medicine for treating the intestinal diseases, and a new strategy is provided for preventing or treating the intestinal diseases.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention provides a preparation process and application of dextran sulfate sodium, and relates to the technical field of catalytic synthesis. The preparation process provided by the invention comprises the following steps: carrying out sulfonation reaction on glucan and a sulfonation reagent under the coaction of an alkali accelerator and a cobalt-based catalyst to obtain glucan sulfate, reacting the glucan sulfate with sodium salt, and refining and separating to obtain glucan sulfate sodium; the cobalt-based catalyst comprises a porous carrier and cobalt nanoparticles growing on the surface of the porous carrier in situ, and the surface of the porous carrier is further coated with a melamine protective layer. The alkali accelerant and the cobalt-based catalyst are used for performing synergistic interaction on the sulfonation reaction, so that the sulfonation reaction can be performed more quickly and efficiently, the waste of reaction time is reduced, the purity of the dextran sodium sulfate can be effectively improved through the refining and separating process, the production efficiency can be improved, and the production cost can be reduced. And the purity and molecular weight stability can be improved by inhibiting side reactions.

The invention discloses a crocodile polypeptide with anti-inflammatory and intestinal flora regulating functions and a preparation method thereof, belongs to the technical field of functional polypeptide preparation, and particularly relates to a preparation method of the crocodile polypeptide, an anti-inflammatory effect of the crocodile polypeptide and a regulating effect of the crocodile polypeptide on intestinal flora in ulcerative colitis inflammation. According to the preparation method, the crocodile polypeptide is prepared by combining multiple physical processing with enzymolysis, so that the purity and the biological activity of the crocodile polypeptide are improved. On the basis, a lipopolysaccharide-induced THP-1 in-vitro cell inflammation model and a dextran sodium sulfate-induced mouse in-vivo ulcerative colitis inflammation model are established, and the in-vivo and in-vitro anti-inflammatory effect of the crocodile polypeptide is further researched. The crocodile polypeptide prepared by the invention has a remarkable inhibition effect on THP-1 cell inflammation induced by lipopolysaccharide. Meanwhile, the crocodile polypeptide prepared by the preparation method disclosed by the invention has an adjusting effect on intestinal flora. The food or functional food with the effects of relieving ulcerative colitis and regulating intestinal flora can be prepared.

The invention discloses a construction method and application of a probiotic engineering bacterium EcNpAm targeting animal intestinal tracts and improving inflammation. According to the present invention, the heterologous expression of the immunomodulatory protein Amuc1100 is successfully achieved through the gene engineering technology by using the Escherichia coli Niss1917 (EcN) as the host and using the anaerobic inducible plasmid pnirBMisL as the expression vector, and the novel engineering bacterium EcNpAm suitable for the animal intestinal anaerobic environment is constructed; furthermore, the expression efficiency of the target protein is represented by fusion expression of green fluorescent protein (GFP). The engineering bacterium is applied to prevention and treatment of animal intestinal inflammation, and successfully realizes targeted delivery of therapeutic protein to intestinal tracts of mice. Experiments show that EcNpAm can effectively relieve typical symptoms such as weight loss, colon shortening, pathological injury, colitis and the like of mice induced by dextran sodium sulfate (DSS) and protect integrity and functions of an intestinal barrier structure.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

The invention provides application of CD84 as a therapeutic target in preparation of drugs for preventing and treating inflammatory bowel diseases, and belongs to the technical field of biological medicines. The CD84 is applied to development, screening or preparation of drugs for preventing and / or treating inflammatory bowel diseases as a therapeutic target. According to the application, a dextran sodium sulfate (DSS)-induced inflammatory bowel disease classical animal model is taken as an experimental subject, and the anti-CD84 antibody is taken as a drug to block the biological function of CD84, so that the degree of DSS-induced mouse enteritis can be effectively relieved, the colorectal length can be recovered, and the secretion level of inflammatory factors can be reduced. Therefore, a new strategy is provided for targeted therapy of the inflammatory bowel disease by taking the CD84 as a therapeutic target.

The invention discloses an application of a bee sugar plum seed alcohol extract in preparation of an anti-colitis medicine. The invention finds that the bee sugar plum seed alcohol extract inhibits the generation of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) under the condition of no cytotoxicity; the bee sugar plum seed alcohol extract inhibits transcription of LPS-induced pro-inflammatory cytokine genes and expression of genes and proteins of synthetic pro-inflammatory mediator enzymes (iNOS and COX-2); the bee sugar plum seed alcohol extract not only inhibits nuclear transfer of NF-kappa B by reducing phosphorylation and degradation of I kappa B alpha, but also inhibits phosphorylation of MPAKs (ERK, p38 and JNK); the traditional Chinese medicine composition has a remarkable inhibition effect on dextran sodium sulfate induced mouse colitis. Therefore, the bee sugar plum seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The invention relates to the field of biological medicine, in particular to polypeptide for inhibiting TBK1 and inflammation and application. The invention provides a series of polypeptides. A cell-penetrating peptide sequence TAT capable of penetrating a cell membrane and a connecting sequence (GSG) are added to the N end of the amino acid sequence of the polypeptides. The sequence can target TBK1 and influence the interaction of TBK1-STING-IRF3 so as to influence the activation of a pathway and achieve the purpose of inhibiting inflammation. The TBK1 targeting peptide LK shows remarkable anti-inflammatory activity in various established mouse inflammation or autoimmune disease models, including a lipopolysaccharide (LPS) induced systemic and acute inflammation model, a dextran sodium sulfate (DSS) induced ulcerative colitis model and a Trex1 defect AGS model. In addition, the polypeptide LK shows even a strong synergistic effect with a PD-1 antibody in cancer immunotherapy in various in vivo tumor models.

The invention discloses a chitosan non-binding bilirubin microsphere as well as a preparation method and application thereof. The chitosan non-binding bilirubin microspheres are prepared by taking chitosan as a delivery carrier and taking chitosan and bilirubin as main raw materials through an emulsion reaction and a cross-linking reaction in sequence. Chitosan (CIS) is selected as a carrier for delivering unbound bilirubin (UCB), and the chitosan unbound bilirubin microspheres are prepared through an emulsion reaction and a cross-linking reaction, so that the UCB is more safely and efficiently fed into the intestinal tract to reach an inflammation part, and experiments prove that the UCB can be used for preparing the unbound bilirubin microspheres. The chitosan non-binding bilirubin microsphere has a remarkable protective effect on the intestinal immune function, microbiota disorder and barrier function of a dextran sodium sulfate (DSS) induced ulcerative colitis (UC) mouse.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and / or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The invention discloses polygonum multiflorum polysaccharide, a preparation method and application of the polygonum multiflorum polysaccharide in preparation of a medicine for treating ulcerative colitis. Polygonum multiflorum polysaccharide is obtained through extraction, deproteinization and column chromatography of Polygonum multiflorum. By establishing a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse model to evaluate the ulcerative colitis resisting effect of the polygonum multiflorum polysaccharide, it is proved that the polygonum multiflorum polysaccharide has the advantages that the weight of the ulcerative colitis model mouse is remarkably increased, the hemafecia index and the loose stool index are remarkably reduced, the colon length is increased, and the ulcerative colitis resisting effect of the polygonum multiflorum polysaccharide is remarkably improved. The richness of intestinal flora is effectively improved, the pathological damage of the colonic tissue of an ulcerative colitis model mouse is effectively improved, and the purpose of treating ulcerative colitis is achieved. Therefore, it is proved for the first time that the polygonum multiflorum polysaccharide has a remarkable ulcerative colitis resisting effect, and an important theoretical basis is provided for development of ulcerative colitis resisting drugs.

The invention provides application of miRNA-148a-3p in preparation of a medicine for relieving inflammation, and belongs to the technical field of biological medicine. In the invention, the miRNA-148a-3p can reduce the expression of p65 and up-regulate the expression level of SIRT1 by targeting Tp65 in a 3'untranslated region of the miRNA-148a-3p so as to relieve inflammatory response and pathological injury degree. Through verification, the miRNA-148a-3p can reduce the expression of p65, up-regulate the expression of SIRT1 gene and inhibit the expression of proinflammatory factors in intestinal tracts of dextran sodium sulfate induced colitis model mice so as to relieve inflammation. Therefore, the camel milk exosome has an important protective effect on prevention and treatment of enteritis by regulating and controlling the miR-148a-3p / p65 / SIRT1 signal channel.

The invention discloses an application of a prunus tomentosa seed alcohol extract in preparation of an anti-colitis medicine. In the invention, the prunus tomentosa seed alcohol extract with the function of resisting colitis is obtained by reflux extraction of prunus tomentosa seeds with 70% ethanol, and has a remarkable inhibition effect on dextran sodium sulfate induced mouse colitis; wherein the weight loss of the mouse is slowed down, the DAI score of the mouse is reduced, the injury of the colon tissue of the mouse is relieved, the content of IL-6, IL-1beta, TNF-alpha and MDA in the colon tissue and serum of the mouse is reduced, and the activity of CAT and SOD in the colon tissue and serum of the mouse is enhanced. The prunus tomentosa seed alcohol extract inhibits the activation of ROS-mediated MAPKs and NF-kappa B pathways, and further inhibits the excessive secretion of proinflammatory mediators NO and PGE2 and proinflammatory cytokines TNF-alpha, IL-6 and IL-1beta in lipopolysaccharide-induced RAW264.7 cells. Therefore, the prunus tomentosa seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The present application discloses isoschaftoside and its compositions and uses. Experiments have proven that isoschaftoside can significantly improve dextran sulfate sodium-induced colitis in mice, specifically manifested as significantly alleviating the weight loss and shortening of colon length caused by the model establishment; significantly reducing the disease activity index and spleen weight of mice; significantly alleviating the pathological changes in the colon tissues of mice, including reducing inflammatory cell infiltration, restoring the crypt structure of the tissue and the number of intestinal glands, and having significant anti-ulcerative colitis activity, showing good application prospects in the preparation of drugs for treating ulcerative colitis.

The invention discloses a preparation method of calcite with different calcium-magnesium ratios, which comprises the following steps of: storing dextran sodium sulfate in a refrigerator, and taking out the dextran sodium sulfate when in use; the method comprises the following steps: adding sodium polyacrylate and dextran sodium sulfate into a centrifuge tube, adding a MgCl2 solution and a CaCl2 solution, mixing, adding a Na2CO3 solution, immediately carrying out a precipitation reaction, completely precipitating all calcium and magnesium ions, and adding reagents in different proportions; after full reaction, immediately carrying out solid-liquid separation by using a centrifugal machine; after reaction liquid is separated, filtering by using a vacuum pump, washing filter residues with deionized water and alcohol for 2-3 times, and drying at room temperature; mixing the prepared calcite powder with deionized water according to the ratio of 0.2 g / 1L, introducing CO2 gas for 6-8 days to ensure that the calcite powder is balanced, and then taking supernate, namely a calcite saturated solution. The invention aims to flexibly prepare calcite solutions with different calcium-magnesium ratios so as to meet diversified application requirements and show extremely high utilization potential and value.

The invention discloses a colon-targeted Pickering emulsion stabilized by rhein-chitosan composite nanoparticles, a preparation method and an application of the colon-targeted Pickering emulsion. Rhein-chitosan is coupled and then crosslinked with sodium tripolyphosphate to form the rhein-chitosan composite nano-particles, and the nano-particles have better hydrophobicity and acid and alkali resistance stability; the nano-particle suspension and fish oil containing rhein are homogenized and emulsified at a high speed to obtain the Pickering emulsion entrapped with the rhein, and the Pickering emulsion has relatively high rhein drug loading capacity, better stability and good colon-specific release and slow release characteristics; and the traditional Chinese medicine composition has a dose-dependent relieving effect on dextran sodium sulfate induced ulcerative colitis mice, can inhibit inflammatory response and repair intestinal barrier functions, can effectively avoid intestinal nutrition loss caused by rhein, and has a good application prospect.

The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LTα, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LTα− / − Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LTα expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

The present invention discloses the application of the sesquiterpene part of wild horsetail in the preparation of a drug for preventing or treating ulcerative colitis. The present invention uses sodium dextran sulfate to induce mice to establish an ulcerative colitis mouse model, and the sesquiterpene part of wild horsetail extracted from wild horsetail is used as a therapeutic drug for treating ulcerative colitis, and then the effect of the sesquiterpene part of wild horsetail on the pharmacological indicators of ulcerative colitis mice is observed. The experimental results show that the sesquiterpene part of wild horsetail can reduce the levels of MPO, C3c, TNF‑α, and IL‑6 in the serum of ulcerative colitis mice, increase the level of IL‑10, improve the level of inflammation in ulcerative colitis mice, inhibit the level of complement, improve colon tissue damage, significantly reduce the DAI score, reduce the degree of shortening of the colon, reduce the symptoms of congestion and swelling of the colon, reduce the spleen index, and show a significant anti-ulcerative colitis effect, which can be used to prepare drugs for the prevention and treatment of ulcerative colitis.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).